Introduction to clinical proteomics

John E. Wiktorowicz, Allan R. Brasier

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Citations (Scopus)

Abstract

Within the context of this section, biomarkers are defined as a panel of proteins and peptides that are predictive of the risk for developing a pathological condition. It is important to note here that the use of the descriptor ‘panel’ is purposeful in that single “biomarkers” are rarely sufficient to permit accurate prediction of a pathological condition. More specifically, the primary application of a biomarker panel is that it serves as a molecular indicator of the severity of a disease or its early response to treatment. In this way, biomarkers enable the application of precision medicine, an approach that tailors specific interventions to those individuals that would most benefit. For a recent comprehensive review of the proteomic-based biomarker development process with a focus on bladder cancer, the reader is directed to Frantzi et al. [Clin Transl Med 3:7, 2014], or a special issue with multiple reviews [Stuhler and Poschmann, Biochim Biophys Acta Proteins Proteomics 1844:859-1058, Elsevier, B V, 2014].

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages435-441
Number of pages7
Volume919
DOIs
StatePublished - 2016

Publication series

NameAdvances in Experimental Medicine and Biology
Volume919
ISSN (Print)00652598
ISSN (Electronic)22148019

Fingerprint

Biomarkers
Proteomics
Precision Medicine
Urinary Bladder Neoplasms
Medicine
Proteins
Peptides

Keywords

  • Clinical proteomics

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Wiktorowicz, J. E., & Brasier, A. R. (2016). Introduction to clinical proteomics. In Advances in Experimental Medicine and Biology (Vol. 919, pp. 435-441). (Advances in Experimental Medicine and Biology; Vol. 919). Springer New York LLC. https://doi.org/10.1007/978-3-319-41448-5_20

Introduction to clinical proteomics. / Wiktorowicz, John E.; Brasier, Allan R.

Advances in Experimental Medicine and Biology. Vol. 919 Springer New York LLC, 2016. p. 435-441 (Advances in Experimental Medicine and Biology; Vol. 919).

Research output: Chapter in Book/Report/Conference proceedingChapter

Wiktorowicz, JE & Brasier, AR 2016, Introduction to clinical proteomics. in Advances in Experimental Medicine and Biology. vol. 919, Advances in Experimental Medicine and Biology, vol. 919, Springer New York LLC, pp. 435-441. https://doi.org/10.1007/978-3-319-41448-5_20
Wiktorowicz JE, Brasier AR. Introduction to clinical proteomics. In Advances in Experimental Medicine and Biology. Vol. 919. Springer New York LLC. 2016. p. 435-441. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-41448-5_20
Wiktorowicz, John E. ; Brasier, Allan R. / Introduction to clinical proteomics. Advances in Experimental Medicine and Biology. Vol. 919 Springer New York LLC, 2016. pp. 435-441 (Advances in Experimental Medicine and Biology).
@inbook{f39cb5e4595f47978040228c283d6708,
title = "Introduction to clinical proteomics",
abstract = "Within the context of this section, biomarkers are defined as a panel of proteins and peptides that are predictive of the risk for developing a pathological condition. It is important to note here that the use of the descriptor ‘panel’ is purposeful in that single “biomarkers” are rarely sufficient to permit accurate prediction of a pathological condition. More specifically, the primary application of a biomarker panel is that it serves as a molecular indicator of the severity of a disease or its early response to treatment. In this way, biomarkers enable the application of precision medicine, an approach that tailors specific interventions to those individuals that would most benefit. For a recent comprehensive review of the proteomic-based biomarker development process with a focus on bladder cancer, the reader is directed to Frantzi et al. [Clin Transl Med 3:7, 2014], or a special issue with multiple reviews [Stuhler and Poschmann, Biochim Biophys Acta Proteins Proteomics 1844:859-1058, Elsevier, B V, 2014].",
keywords = "Clinical proteomics",
author = "Wiktorowicz, {John E.} and Brasier, {Allan R.}",
year = "2016",
doi = "10.1007/978-3-319-41448-5_20",
language = "English (US)",
volume = "919",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "435--441",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Introduction to clinical proteomics

AU - Wiktorowicz, John E.

AU - Brasier, Allan R.

PY - 2016

Y1 - 2016

N2 - Within the context of this section, biomarkers are defined as a panel of proteins and peptides that are predictive of the risk for developing a pathological condition. It is important to note here that the use of the descriptor ‘panel’ is purposeful in that single “biomarkers” are rarely sufficient to permit accurate prediction of a pathological condition. More specifically, the primary application of a biomarker panel is that it serves as a molecular indicator of the severity of a disease or its early response to treatment. In this way, biomarkers enable the application of precision medicine, an approach that tailors specific interventions to those individuals that would most benefit. For a recent comprehensive review of the proteomic-based biomarker development process with a focus on bladder cancer, the reader is directed to Frantzi et al. [Clin Transl Med 3:7, 2014], or a special issue with multiple reviews [Stuhler and Poschmann, Biochim Biophys Acta Proteins Proteomics 1844:859-1058, Elsevier, B V, 2014].

AB - Within the context of this section, biomarkers are defined as a panel of proteins and peptides that are predictive of the risk for developing a pathological condition. It is important to note here that the use of the descriptor ‘panel’ is purposeful in that single “biomarkers” are rarely sufficient to permit accurate prediction of a pathological condition. More specifically, the primary application of a biomarker panel is that it serves as a molecular indicator of the severity of a disease or its early response to treatment. In this way, biomarkers enable the application of precision medicine, an approach that tailors specific interventions to those individuals that would most benefit. For a recent comprehensive review of the proteomic-based biomarker development process with a focus on bladder cancer, the reader is directed to Frantzi et al. [Clin Transl Med 3:7, 2014], or a special issue with multiple reviews [Stuhler and Poschmann, Biochim Biophys Acta Proteins Proteomics 1844:859-1058, Elsevier, B V, 2014].

KW - Clinical proteomics

UR - http://www.scopus.com/inward/record.url?scp=85006385021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006385021&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-41448-5_20

DO - 10.1007/978-3-319-41448-5_20

M3 - Chapter

C2 - 27975229

AN - SCOPUS:85006385021

VL - 919

T3 - Advances in Experimental Medicine and Biology

SP - 435

EP - 441

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -